IDSA News - June 2012  (Plain Text Version)

Return to Graphical Version


In this issue:
Patient Care and Science
•  ACIP Adjusts Influenza Vaccine Dosing for Young Children
•  CDC Updates Recommendations for Carbapenem-Resistant Enterobacteriaceae
•  New Guideline Pocketcards: Rhinosinusitis and Diabetic Foot Infection
Clinical Practice Management
•  IDSA Weighs In on CMS Inpatient Proposed Rule
Global ID
•  “Cured” HIV Patient, Researchers Discuss AIDS Fight
•  WHO: Pregnant Women with HIV Should Have Access to Optimal Drug
•  TB Treatment Trial Raises Hopes
Policy and Advocacy
•  IDSA Supports Universal Vaccination Through State Mandates
•  IDSA Leads Support for Increased BARDA Funding
•  IDSA Supports Age-Based HCV Screening Guidelines
•  Society Comments on Federal Action Plan to Prevent HAIs
Your Colleagues
•  Check Out “My IDSA” for Latest Member News
Education & Resources
•  Clinical Microbiology Learning Tool Available Online
•  How to Manage Information Overload
Top Stories
•  Congress Passes Antibiotic Incentives Legislation
•  Supreme Court Upholds Health Care Reform Law
•  EIN Update: CDC Encourages Submission of Suspected C. gattii Isolates
•  IDSA Journal Club


ACIP Adjusts Influenza Vaccine Dosing for Young Children

The federal Advisory Committee on Immunization Practices (ACIP) recently updated its recommendation on the number of vaccine doses young children should receive during the upcoming influenza season.

Children ages 6 months through 8 years will require two doses of vaccine this season if they have not been previously vaccinated with at least one vaccine dose containing the 2009 A H1N1 strain, which was included in the 2009 monovalent influenza vaccine and in the 2010-2012 seasonal vaccine, according to Jeffrey S. Duchin, MD, FIDSA, who attended the June 20-21 ACIP meeting. The approach is already supported by the American Academy of Pediatrics. ACIP members also heard updates on vaccine effectiveness and safety during the previous influenza season. For a summary, see CIDRAP News.

In addition, the committee voted to recommend a combination regimen of pneumococcal polysaccharide vaccine and the 13-valent pneumococcal conjugate vaccine for immunocompromised adults. The recommendation may present some challenges in communication to providers and in implementation, given variations that depend upon whether an adult is naïve to pneumococcal vaccination or has previously received polysaccharide vaccine, as well as timing issues, noted William Schaffner, MD, FIDSA, who also attended the meeting.

Committee members also discussed safety and efficacy data for the human papillomavirus vaccine, protections against hepatitis B among health care workers, a new combination meningococcal vaccine recently licensed in the U.S., post-exposure prophylaxis for measles with immune globulin, and the current poor state of adult vaccination coverage in the U.S.

ACIP recommendations become official once approved by the Centers for Disease Control and Prevention (CDC) and published in the MMWR. Meeting presentations will be available shortly on CDC’s website: